Aside from radiation (WBRT or SRS), what is your approach to patients with EGFR-mutated or ALK-translocated metastatic NSCLC who have systemic disease control but fail in the CNS?

Topics: Lung Cancer • Thoracic Malignancies • Medical Oncology • Brain Metastases

Do you increase dosage of the TKI or switch to a different generation TKI? How does your answer differ for EGFR vs. ALK, and for discerete brain metastases vs. leptomeningeal disease?

Answer from: Medical Oncologist at Academic Institution

While there are systemic agents that have brain penetration, my most standard treatment remains radiotherapy. That said, the questions specifically asked about non-XRT options. I do think about parenchymal brain metastases and LMD a bit differently. For LMD in EGFR-mutated NSCLC, I do ...

Comments

Radiation Oncologist at Yale School of Medicine
For patients with ALK-translocated NSCLC and asymp...

Related Questions